Karen Hager
@Blue Owl Capital Holdings Lp
Latest period2024 - Q3ReportedManaged Assets$518.429BTotal holdings137
Assets growth rate144084.03%Assets growth rate (2-Q avg)72027.93%Continuous growth in asset value1 quarters
Portfolio positions
This chart displays the top 10 holdings in Blue Owl Capital Holdings Lp's 2024 - Q3 portfolio, based on their 13F SEC filing, out of a total of 137 positions.
Assets under management
The assets under management (AUM) of Blue Owl Capital Holdings Lp over the past 10 years (40 quarters) show continuous growth in total asset value over the last 1 quarters. As of the latest 13F SEC filing for 2024 - Q3, they manage 518.429B in assets, with a quarterly growth rate of 144084.03% and a 2-quarter average growth rate of 72027.93%. The portfolio is managed by Karen Hager, and others.
Portfolio holdings
Investment | Portfolio % | Reported Value | Recent Activity |
---|---|---|---|
LRMRLarimar Therapeutics Inc
| 5.27% | $27.293B 4.167M shares@ $6550.01 avg price | Increased 7.97% |
ENGNEngene Holdings Inc
| 3.9% | $20.189B 3.059M shares@ $6600.0 avg price | Increased 24.87% |
CNTXContext Therapeutics Inc
| 2.05% | $10.606B 5.411M shares@ $1960.0 avg price | Increased 4.85% |
AQSTAquestive Therapeutics Inc
| 1.18% | $6.1B 1.225M shares@ $4980.0 avg price | Increased 7.46% |
CMPXCompass Therapeutics Inc
| 1.03% | $5.299B 2.88M shares@ $1840.0 avg price | Increased 1.77% |
PYXSPyxis Oncology Inc
| 0.8% | $4.133B 1.126M shares@ $3670.01 avg price | Increased 7.65% |
JANXJanux Therapeutics Inc
| 0.71% | $3.634B 80,000 shares@ $45430.0 avg price | Increased 100% |
GPCRStructure Therapeutics Inc
| 0.56% | $2.853B 65,000 shares@ $43890.0 avg price | Increased 18.19% |
SYRSSyros Pharmaceuticals Inc
| 0.22% | $1.109B 515,855 shares@ $2150.0 avg price | Increased 51.35% |
ENGNWEngene Holdings Inc
| 0.15% | $728.427M 511,177 shares@ $1425.0 avg price | Increased 898.85% |